
    
      Interventional cardiology was revolutionized by the invention of stents, initially with the
      bare-metal stents (BMS) and recently with the drug-eluting stents (DES).Zotarolimus-eluting
      stents have shown promising results in randomized clinical trails, demonstrating a reduction
      of clinical and angiographic restenosis in comparison to BMS, and comparable
      clinically-driven target lesion revascularization rates in comparison with Sirolimus-eluting
      stents. While short-term and 1 year registry data is available from outside of the United
      States, it will be important to collect "real-world" data regarding the stent usage and
      outcomes in the United States. In this study we propose to follow patients who received at
      least one EndeavorÂ® Stent as primary treatment for ACS for up to 3 years post initial stent
      implantation.
    
  